Concepedia

A. Dallob

AD

6

Publications

943

Citations

6

H-Index

1994

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

KU Leuven

Dana-Farber Cancer Institute

A. Dallob is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top concepts

Publications per year

1994–2006

6

Publications

6

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

Elliot Ehrich, A. Dallob, I Delepeleire et al. · Clinical Pharmacology & Therapeutics · 1999 · 326 citations

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias

D. J. Deangelo, Richard M. Stone, L. B. Silverman et al. · Journal of Clinical Oncology · 2006 · 226 citations

, , +18

The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.

A. Dallob, Neil S. Sadick, Walter Unger et al. · The Journal of Clinical Endocrinology & Metabolism · 1994 · 197 citations

, , +12

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

Marleen Depré, Elliot Ehrich, Anne Van Hecken et al. · European Journal of Clinical Pharmacology · 2000 · 93 citations

, , +7

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production

Nicholas J. Wight, Keith Gottesdiener, Nigel Garlick et al. · Gastroenterology · 2001 · 62 citations · Full text

, , +6

Rows per page

1–5 of 6